Filters

June Mason, Gerard J M Bruin, Klaus Seuwen, Lloyd B Klickstein, Linda Mindeholm, Rossella Belleli, Juergen Loeffler, Evita Harfst, Markus R John, Leo Widler, Michaela Kneissel

Bone 2015;64():204-10

Full Text

Abstract

Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.

R V Sriram Uday, Rajdip Misra, Annaram Harika, Sandip Dolui, Achintya Saha, Uttam Pal, V Ravichandiran, Nakul C Maiti

PloS one 2021;16(9):e0257206

Free Full Text

Abstract

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

Satoshi Honda, Kohei Takata, Susan W Kim, Jordan Andrews, Peter J Psaltis, Michael Sweeney, Ewelina Kulikowski, Jan Johansson, Norman C W Wong, Stephen J Nicholls, Daisuke Shishikura, Yu Kataoka

American journal of cardiovascular drugs : drugs, devices, and other interventions 2019;19(1):49-57

Full Text

Abstract

Clinical drug interaction profile of idelalisib in healthy subjects.

Srini Ramanathan, Bernard Murray, Sibylle Wilbert, Candra Moyer, Huafeng Zhou, Michelle Robeson, Feng Jin

Journal of clinical pharmacology 2016;55(8):909-19

Full Text

Abstract

Novel therapy in the treatment of scleroderma.

S D Sule, F M Wigley

Expert opinion on investigational drugs 2001;10(1):31-48

Full Text

Abstract

Gastrointestinal and Pancreatic Manifestations of Cystic Fibrosis in the Era of Highly Effective Modulators.

Sasha-Jane Abi-Aad, Sridevi Narayanan, Racha T Khalaf

Advances in pediatrics 2026;73(1):179-190

Full Text

Abstract

Results: 1 – 15 / 33

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Quinazolinones""[mesh_terms]

Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases.

Schiff's bases of quinazolinone derivatives: Synthesis and SAR studies of a novel series of potential anti-inflammatory and antioxidants.

Discovery of Potent and Novel Quinazolinone Sulfide Inhibitors with Anti-ToCV Activity.

Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.

Evaluation of Chemically-Cleavable Linkers for Quantitative Mapping of Small Molecule-Cysteinome Reactivity.

Quinazolinone and Phthalazinone Inhibitors of the HDAC6/Ubiquitin Protein-Protein Interaction.

Potential nonhormonal therapeutics for medical treatment of leiomyomas.

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.

Design, synthesis and activity evaluation of novel quinazolinone compounds as TRPC5 inhibitors.

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

Clinical drug interaction profile of idelalisib in healthy subjects.

Novel therapy in the treatment of scleroderma.

Gastrointestinal and Pancreatic Manifestations of Cystic Fibrosis in the Era of Highly Effective Modulators.

Results for
""Quinazolinones""[mesh_terms]